FALON POLLIFRONE: Open Payments
NPI 1376184655 · LIVONIA, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,471 in 81 payments from 18 companies in 2025. Trend: 2023 $1,412 · 2024 $1,281 · 2025 $1,471
Food & beverage: $1,471
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 10 | $253 |
| ABBVIE INC. | 10 | $176 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $151 |
| Alkermes, Inc. | 6 | $147 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| Corium, LLC | 8 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| Lundbeck LLC | 4 | $65 |
| Neurocrine BioSciences, Inc. | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
Products named: COBENFY, VRAYLAR, CAPLYTA, ARISTADA, REXULTI, Azstarys, FANAPT, INGREZZA.
Industry payments across MI — which companies pay providers there.
